SeQure DX

Sequre dx email format

Verified email-pattern data for Sequre Dx is currently limited. You can still use the company insights and contact sections below.
SeQure DX™ is setting the standard for precision analytics in gene editing, delivering best-in-class off-target risk assessment services to advance safer, more effective cell and gene therapies. We provide a comprehensive suite of trusted assays—such as ONE-seq®, GUIDE-seq™, DEUX-seq™, Amplicon-seq™, Guide Profiler™, Guide Select™, and SAFER Detection™—that enable developers to detect, nominate, and confirm gene editing outcomes with high sensitivity and regulatory alignment. In January 2025, SeQure DX™ was acquired by MaxCyte, Inc., a leading cell engineering company, to form the core of MaxCyte’s Cell & Gene Therapy (CGT) Services business. Together, we provide an integrated solution that combines world-class cell engineering and comprehensive gene editing risk assessment services, helping therapeutic developers mitigate risk in their programs, accelerate timelines, and enable regulatory confidence from discovery through clinical stage and beyond.
Looking for a particular SeQure DX employee's phone or email?

Sequre Dx Questions

Explore related pages

Related company profiles:

Top SeQure DX Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant